A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer

Exclusion Criteria

• •Clinically significant cardiovascular disease: New York Heart Association (NYHA) class III or IV chronic congestive heart failure, coronary heart disease (myocardial infarction within 6 months); cardiac arrhythmia requiring anti-arrhythmic drug (beta-blocker or digoxin is allowed to be used); uncontrolled high blood pressure
• •HIV infection
• •Acute exacerbation of chronic hepatitis A or hepatitis B infection
• •The subject has uncontrollable seizures required pharmacotherapy (such as steroids or antiepileptic drugs)
• •The subject has a history of allogeneic organ transplants
• •Subject with irregular hemorrhagic disease
• •The subject receives dialysis treatment The subject has a history of other malignant tumor except subjects with curable basal cell carcinoma, superficial bladder tumor or other tumors has been cured over three years of study entry
• •The subject has a history of gastrointestinal hemorrhage within 30 days of study entry
• •The subject has an allergic history or is allergic to the drug in this study
• •The subject has serious diseases of respiratory, nervous or mental system
• •Subject with immune disease, auto-immune disease requires systemic ongoing immunosuppressive therapy
• •The subject has problems with drug or alcohol abuse
• •Major surgery within 4 weeks of enrollment
• •Prior autologous bone marrow transplantation within 4 weeks of enrollment
• •The subject has participated in any other therapeutic clinical trial with an experimental drug in the 4 weeks prior to this trial
• •The subject has any other unsuitable or adverse condition to be determined by the investigator
• •Any medical intervention or any circumstances that could compromise the safety and compliance of the trial subjects